Tirzepatide vs Mazdutide.

Tirzepatide (development code LY3298176) is a synthetic, 39-amino-acid modified peptide engineered as a "twincretin," a single molecule that activates two incretin hormone receptors at once. It carries a C20 fatty diacid side chain that binds serum albumin, extending its half-life to roughly five days and enabling once-weekly subcutaneous dosing. It is the active ingredient in Eli Lilly's FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea).

Mazdutide (IBI362, originally LY3305677) is an investigational once-weekly injectable dual agonist of the GLP-1 and glucagon receptors, based on a mammalian oxyntomodulin analog. It is being developed by Innovent Biologics under a license from Eli Lilly, primarily for obesity and type 2 diabetes and with additional metabolic indications under study. It is furthest advanced in China, where it has progressed through Phase 3 trials, but it is not an approved medicine in the United States or Europe. Like other dual agonists, it is designed to pair appetite and glucose control with added energy expenditure.

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, the first approved agent to engage both incretin pathways. Through GLP-1 receptor activation it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via central pathways; GIP receptor activation contributes additional insulinotropic effects and is thought to influence energy metabolism and adipose tissue handling. Its peptide backbone is more closely modeled on native GIP, and it is biased toward GIP-receptor engagement relative to GLP-1, though the precise contribution of the GIP arm to its clinical effect in humans remains an area of active investigation. The net clinical result is improved glycemic control and substantial reductions in body weight and food intake.

Mazdutide derives from oxyntomodulin, a natural gut hormone that engages both the GLP-1 and glucagon receptors. GLP-1 activation drives appetite suppression, delayed gastric emptying, and glucose-dependent insulin release, while glucagon-receptor activation is thought to increase energy expenditure and reduce hepatic fat. The combined signaling is intended to produce weight loss alongside improvements in lipids, blood pressure, liver enzymes and other metabolic markers. Structural modifications extend its half-life to allow weekly subcutaneous administration.

Human evidence for tirzepatide is unusually robust, anchored by the large randomized SURPASS (diabetes) and SURMOUNT (obesity) programs. In SURPASS-2 (Frias et al., NEJM 2021), tirzepatide produced greater HbA1c and body-weight reductions than injectable semaglutide in type 2 diabetes across all doses. In the placebo-controlled SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), adults with obesity or overweight lost roughly 15–21% of body weight on average depending on dose. SURMOUNT-OSA (Malhotra et al., NEJM 2024) showed reductions in apnea-hypopnea index in patients with obesity and moderate-to-severe obstructive sleep apnea, supporting the December 2024 FDA approval for that indication. A dedicated cardiovascular outcomes trial (SURPASS-CVOT) and the SUMMIT heart-failure-with-preserved-ejection-fraction program have reported results, but long-term hard-outcome data are newer and still being integrated; readers should treat cardiovascular benefit as supported but more recently established than the glycemic and weight findings.

A randomised, double-blind, placebo-controlled Phase 2 trial in 248 Chinese adults with overweight or obesity, published in Nature Communications (2023), tested mazdutide 3 mg, 4.5 mg and 6 mg over 24 weeks. Mean body-weight reductions reached roughly 11% at the 6 mg dose versus about 3% with placebo, with dose-dependent effects. Participants also showed improvements in waist circumference, blood pressure, blood lipids, liver transaminases and serum uric acid. Earlier Phase 1b studies in Chinese adults with overweight/obesity and with type 2 diabetes supported tolerability and metabolic benefit at higher doses. Phase 3 obesity and diabetes programs (the GLORY series) have since been conducted in China, and GLORY-1, a randomised placebo-controlled Phase 3 trial of once-weekly mazdutide in Chinese adults with obesity or overweight, was published in the New England Journal of Medicine in 2025. A further Phase 2 randomised controlled trial in Chinese adults with a body mass index of at least 30 and without diabetes was reported in Med, and mazdutide has been included in network meta-analyses of glucagon receptor agonists that pool metabolic outcomes across compounds. Evidence outside Chinese populations and long-term outcome data remain limited. The trials are sponsor-run, of moderate size, and almost entirely single-country, so generalisability to other ancestries, body-composition distributions and background diets is untested. There is no cardiovascular outcome trial for mazdutide, no published head-to-head randomised comparison with semaglutide or tirzepatide, and no multi-year durability or weight-regain dataset. By contrast, semaglutide and tirzepatide each have global multi-thousand-participant Phase 3 programs and regulatory approval in the United States and Europe, and semaglutide additionally has dedicated cardiovascular outcome data, which places mazdutide an evidence tier behind them despite broadly similar reported weight reductions. Regulatory acceptance in one country also does not substitute for the outcome evidence that has not yet been generated.

The most common adverse effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and decreased appetite, typically arising during dose escalation and often diminishing over time. The FDA label carries a boxed warning regarding thyroid C-cell tumors based on rodent studies (the human relevance is unknown), and it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Documented risks include acute pancreatitis, gallbladder disease, acute kidney injury (often via dehydration from GI losses), hypersensitivity reactions, and hypoglycemia when combined with insulin or sulfonylureas. Important unknowns remain around long-term safety, effects of regained weight after discontinuation, use in pregnancy, and potential reduced effectiveness of oral medications (including oral contraceptives) due to delayed gastric emptying.

Across trials, the most common adverse events were gastrointestinal, including nausea, diarrhoea and decreased appetite, typical of GLP-1-based agents and generally most pronounced during dose escalation. Overall tolerability was described as favorable in the Phase 2 study, but as an investigational drug its full safety profile, including uncommon and long-term risks, is not yet established. Glucagon-receptor activation warrants monitoring of parameters such as heart rate and hepatic markers in ongoing studies. Documented class considerations for incretin-based agents include gallbladder and biliary events, reported pancreatitis, delayed gastric emptying with implications for sedation and anaesthesia, loss of lean mass in parallel with fat loss, and rodent thyroid C-cell findings that shaped labelling for several approved GLP-1 drugs. A trial adequate to characterise these requires scheduled laboratory chemistry, vital-sign monitoring, pregnancy prevention requirements, protocol-defined dose-reduction and stopping rules, and independent adjudication of serious events, none of which exists outside a regulated study. Mazdutide is not approved or commercially supplied in the United States or Europe, so material sold there as mazdutide comes from unregulated research-chemical or compounding channels with no verified identity, potency, purity or sterility, no stability data, and no route for reporting harm. Peptide products from such channels have been associated with mislabelling and contamination, which makes any observed effect, benign or adverse, difficult to attribute to the intended molecule.

Tirzepatide is FDA-approved (not investigational): as Mounjaro for type 2 diabetes (May 2022) and as Zepbound for chronic weight management (November 2023) and moderate-to-severe obstructive sleep apnea in adults with obesity (December 2024); it is also authorized in the EU, UK, and other jurisdictions. It is a prescription drug, and compounded or research-grade "tirzepatide" sold outside the regulated supply chain is not FDA-approved and carries quality and safety risks.

Mazdutide is investigational and not approved by the FDA or EMA. Its development is most advanced in China, where a regulatory filing for obesity/overweight has been pursued following Phase 3 results. Any use outside an authorized clinical trial is unapproved.